+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Opioids Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 292 Pages
  • May 2024
  • Region: Global
  • Fairfield Market Research
  • ID: 5972686
The global opioids market, valued at US$ 45.78 Bn in 2024, is projected to grow at a CAGR of 3.3%, reaching US$ 57.46 Bn by 2031. The market's expansion is primarily driven by the rising number of patients with chronic diseases such as cancer and Chronic Obstructive Pulmonary Disease (COPD), increased prescriptions for post-operative pain relief, and heightened awareness of pain management solutions.

Morphine to Lead Market Value in Opioids Segment

According to the publisher, morphine is anticipated to hold the largest market value within the opioids segment. The opioids market accounts for approximately 55.6% of the revenue share in the global analgesics market, which is valued in the billions of dollars.

Drivers of Market Growth

1. Increasing Prevalence of Chronic Diseases

The growing number of patients with chronic diseases significantly contributes to the demand for opioids. For instance, a 2020 study by the World Health Organization (WHO) reported that COPD was the third leading cause of mortality worldwide, with a combined prevalence of 15.70% in men and 9.93% in women. Additionally, the rising incidence of cancer, which saw around 19.3 million cases and 10 million cancer-related deaths globally in 2020, is a critical driver. With 50 to 70 percent of cancer patients requiring analgesics to manage their pain, the increasing cancer burden, expected to reach 21.7 million cases by 2030, will further fuel the demand for opioids.

2. Neuropathic Pain

The prevalence of neuropathic pain is another significant factor. According to a study by the National Center for Biotechnology Information (NCBI), 14.6% of individuals suffer from neuropathic pain, with 25.1% experiencing genetic or idiopathic neuropathy and 27.3% suffering from neck and back pain. This prevalence is anticipated to surge, driving the demand for opioids.

3. Demographic Expansion

The expansion of companies providing novel and affordable opioids, especially in African and South American countries, is expected to uplift the market. Companies holding patent rights to specific opioid medications are focusing on these potential markets and seeking permissions from relevant government authorities to commercialize their products.

4. Rising Awareness in Pain Management

Increased awareness of opioids in pain management, particularly for moderate to severe pain, contributes to market growth. The introduction of Opioids Maintenance Treatment (OMT) and palliative care programs has led to a higher demand for opioids. The National Institute of Health (NIH) highlights that some prescribed opioids can also treat conditions such as cough and diarrhea, broadening their application.

5. Chronic Disease Management

The demand for opioids is further driven by the increased prescription of painkillers during post-operative procedures and for patients with terminally chronic diseases, including HIV and severe lung infections. Local governments, NGOs, regulatory agencies, and healthcare systems are promoting pain management awareness programs, increasing the use of opioid medications.

Challenges to Market Growth

1. Abuse and Misuse of Opioids

The severity of opioid abuse and misuse has led practitioners to reduce opioid prescriptions, impacting overall sales. According to the International Association for the Study of Pain (IASP), 20-30% of opioids prescribed for chronic pain are misused, and up to 10% of all opioid users are addicted.

2. Adverse Side Effects

Chronic use of opioids like morphine can lead to severe side effects, including respiratory depression, coma, and even death. Long-term use can result in physical and psychological addiction and immune system degradation. Additionally, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), often used alongside opioids, have side effects affecting the cardiovascular, gastrointestinal, and excretory systems.

Regulatory Frameworks

Clinical practice standards impose strict restrictions on opioid prescriptions to ensure patient safety and prevent overuse, abuse, and overdose. The Secretary of Health and Human Services (HHS) is mandated to ensure the safe use of prescription medications with abuse potential under Section 1122 of the Food Drug and Cosmetics Act (FDASIA).

Future Outlook

The opioids market is poised for growth driven by the increasing prevalence of chronic diseases, demographic expansion, and rising awareness in pain management. As companies continue to innovate and expand into emerging markets, the demand for opioids is expected to rise significantly. However, addressing the challenges of abuse, misuse, and adverse side effects remains crucial for sustainable market growth.

Key Market Players:

  • Pfizer, Inc.
  • Boehringer Ingelheim International GmbH
  • Janssen Pharmaceuticals, Inc.
  • Sanofi SAIS
  • Sun Pharmaceutical Industries Ltd.
  • Actavis Plc. [Teva Pharmaceutical Industries Ltd.]
  • Mallinckrodt Pharmaceuticals
  • Endo Pharmaceuticals Inc. [Endo International plc]
  • Purdue Pharma L.P.
  • Assertio Therapeutics, Inc. (Assertio Holdings, Inc.)

Global Opioids Market is Segmented as Below:

By Product:

  • Morphine
  • Codiene
  • Fentanyl
  • Meperidine
  • Methadone

By Application:

  • Cough Suppression
  • Analgesia
  • Diarrhea Suppression

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Store
  • Clinics
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Opioids Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Product Adoption
2.4. Value Chain Analysis
2.5. Product USP Analysis
2.6. Pipeline Assessment
2.7. Porter’s Five Forces Analysis
2.8. COVID-19 Impact Analysis
2.8.1. Supply
2.8.2. Demand
2.9. Economic Overview
2.9.1. World Economic Projections 2.10.PESTLE Analysis
3. Global Opioids Market Outlook, 2018 - 2031
3.1. Global Opioids Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Morphine
3.1.1.2. Codiene
3.1.1.3. Fentanyl
3.1.1.4. Meperidine
3.1.1.5. Methadone
3.2. Global Opioids Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Analgesia
3.2.1.2. Cough Suppression
3.2.1.3. Diarrhea Suppression
3.3. Global Opioids Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Hospital Pharmacies
3.3.1.2. Retail Pharmacies
3.3.1.3. Drug Store
3.3.1.4. Clinics
3.3.1.5. Others
3.4. Global Opioids Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Opioids Market Outlook, 2018 - 2031
4.1. North America Opioids Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Morphine
4.1.1.2. Codiene
4.1.1.3. Fentanyl
4.1.1.4. Meperidine
4.1.1.5. Methadone
4.2. North America Opioids Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Analgesia
4.2.1.2. Cough Suppression
4.2.1.3. Diarrhea Suppression
4.3. North America Opioids Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Hospital Pharmacies
4.3.1.2. Retail Pharmacies
4.3.1.3. Drug Store
4.3.1.4. Clinics
4.3.1.5. Others
4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Opioids Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. U.S. Opioids Market by Product, Value (US$ Bn), 2018 - 2031
4.4.1.2. U.S. Opioids Market by Application, Value (US$ Bn), 2018 - 2031
4.4.1.3. U.S. Opioids Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.4.1.4. Canada Opioids Market by Product, Value (US$ Bn), 2018 - 2031
4.4.1.5. Canada Opioids Market by Application, Value (US$ Bn), 2018 - 2031
4.4.1.6. Canada Opioids Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Opioids Market Outlook, 2018 - 2031
5.1. Europe Opioids Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Morphine
5.1.1.2. Codiene
5.1.1.3. Fentanyl
5.1.1.4. Meperidine
5.1.1.5. Methadone
5.2. Europe Opioids Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Analgesia
5.2.1.2. Cough Suppression
5.2.1.3. Diarrhea Suppression
5.3. Europe Opioids Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Hospital Pharmacies
5.3.1.2. Retail Pharmacies
5.3.1.3. Drug Store
5.3.1.4. Clinics
5.3.1.5. Others
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Opioids Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Germany Opioids Market by Product, Value (US$ Bn), 2018 - 2031
5.4.1.2. Germany Opioids Market by Application, Value (US$ Bn), 2018 - 2031
5.4.1.3. Germany Opioids Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.4. U.K. Opioids Market by Product, Value (US$ Bn), 2018 - 2031
5.4.1.5. U.K. Opioids Market by Application, Value (US$ Bn), 2018 - 2031
5.4.1.6. U.K. Opioids Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.7. France Opioids Market by Product, Value (US$ Bn), 2018 - 2031
5.4.1.8. France Opioids Market by Application, Value (US$ Bn), 2018 - 2031
5.4.1.9. France Opioids Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.10. Italy Opioids Market by Product, Value (US$ Bn), 2018 - 2031
5.4.1.11. Italy Opioids Market by Application, Value (US$ Bn), 2018 - 2031
5.4.1.12. Italy Opioids Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.13. Turkey Opioids Market by Product, Value (US$ Bn), 2018 - 2031
5.4.1.14. Turkey Opioids Market by Application, Value (US$ Bn), 2018 - 2031
5.4.1.15. Turkey Opioids Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.16. Russia Opioids Market by Product, Value (US$ Bn), 2018 - 2031
5.4.1.17. Russia Opioids Market by Application, Value (US$ Bn), 2018 - 2031
5.4.1.18. Russia Opioids Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.19. Rest of Europe Opioids Market by Product, Value (US$ Bn), 2018 - 2031
5.4.1.20. Rest of Europe Opioids Market by Application, Value (US$ Bn), 2018 - 2031
5.4.1.21. Rest of Europe Opioids Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Opioids Market Outlook, 2018 - 2031
6.1. Asia Pacific Opioids Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Morphine
6.1.1.2. Codiene
6.1.1.3. Fentanyl
6.1.1.4. Meperidine
6.1.1.5. Methadone
6.2. Asia Pacific Opioids Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Analgesia
6.2.1.2. Cough Suppression
6.2.1.3. Diarrhea Suppression
6.3. Asia Pacific Opioids Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Hospital Pharmacies
6.3.1.2. Retail Pharmacies
6.3.1.3. Drug Store
6.3.1.4. Clinics
6.3.1.5. Others
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Opioids Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. China Opioids Market by Product, Value (US$ Bn), 2018 - 2031
6.4.1.2. China Opioids Market by Application, Value (US$ Bn), 2018 - 2031
6.4.1.3. China Opioids Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.4. Japan Opioids Market by Product, Value (US$ Bn), 2018 - 2031
6.4.1.5. Japan Opioids Market by Application, Value (US$ Bn), 2018 - 2031
6.4.1.6. Japan Opioids Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.7. South Korea Opioids Market by Product, Value (US$ Bn), 2018 - 2031
6.4.1.8. South Korea Opioids Market by Application, Value (US$ Bn), 2018 - 2031
6.4.1.9. South Korea Opioids Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.10. India Opioids Market by Product, Value (US$ Bn), 2018 - 2031
6.4.1.11. India Opioids Market by Application, Value (US$ Bn), 2018 - 2031
6.4.1.12. India Opioids Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.13. Southeast Asia Opioids Market by Product, Value (US$ Bn), 2018 - 2031
6.4.1.14. Southeast Asia Opioids Market by Application, Value (US$ Bn), 2018 - 2031
6.4.1.15. Southeast Asia Opioids Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.16. Rest of Asia Pacific Opioids Market by Product, Value (US$ Bn), 2018 - 2031
6.4.1.17. Rest of Asia Pacific Opioids Market by Application, Value (US$ Bn), 2018 - 2031
6.4.1.18. Rest of Asia Pacific Opioids Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Opioids Market Outlook, 2018 - 2031
7.1. Latin America Opioids Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Morphine
7.1.1.2. Codiene
7.1.1.3. Fentanyl
7.1.1.4. Meperidine
7.1.1.5. Methadone
7.2. Latin America Opioids Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
7.2.1. Key Highlights
7.2.1.1. Analgesia
7.2.1.2. Cough Suppression
7.2.1.3. Diarrhea Suppression
7.3. Latin America Opioids Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Hospital Pharmacies
7.3.1.2. Retail Pharmacies
7.3.1.3. Drug Store
7.3.1.4. Clinics
7.3.1.5. Others
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Opioids Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Opioids Market by Product, Value (US$ Bn), 2018 - 2031
7.4.1.2. Brazil Opioids Market by Application, Value (US$ Bn), 2018 - 2031
7.4.1.3. Brazil Opioids Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1.4. Mexico Opioids Market by Product, Value (US$ Bn), 2018 - 2031
7.4.1.5. Mexico Opioids Market by Application, Value (US$ Bn), 2018 - 2031
7.4.1.6. Mexico Opioids Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1.7. Argentina Opioids Market by Product, Value (US$ Bn), 2018 - 2031
7.4.1.8. Argentina Opioids Market by Application, Value (US$ Bn), 2018 - 2031
7.4.1.9. Argentina Opioids Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1.10. Rest of Latin America Opioids Market by Product, Value (US$ Bn), 2018 - 2031
7.4.1.11. Rest of Latin America Opioids Market by Application, Value (US$ Bn), 2018 - 2031
7.4.1.12. Rest of Latin America Opioids Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Opioids Market Outlook, 2018 - 2031
8.1. Middle East & Africa Opioids Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Morphine
8.1.1.2. Codiene
8.1.1.3. Fentanyl
8.1.1.4. Meperidine
8.1.1.5. Methadone
8.2. Middle East & Africa Opioids Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Analgesia
8.2.1.2. Cough Suppression
8.2.1.3. Diarrhea Suppression
8.3. Middle East & Africa Opioids Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Hospital Pharmacies
8.3.1.2. Retail Pharmacies
8.3.1.3. Drug Store
8.3.1.4. Clinics
8.3.1.5. Others
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Opioids Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. GCC Opioids Market by Product, Value (US$ Bn), 2018 - 2031
8.4.1.2. GCC Opioids Market by Application, Value (US$ Bn), 2018 - 2031
8.4.1.3. GCC Opioids Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.4. South Africa Opioids Market by Product, Value (US$ Bn), 2018 - 2031
8.4.1.5. South Africa Opioids Market by Application, Value (US$ Bn), 2018 - 2031
8.4.1.6. South Africa Opioids Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.7. Egypt Opioids Market by Product, Value (US$ Bn), 2018 - 2031
8.4.1.8. Egypt Opioids Market by Application, Value (US$ Bn), 2018 - 2031
8.4.1.9. Egypt Opioids Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.10. Nigeria Opioids Market by Product, Value (US$ Bn), 2018 - 2031
8.4.1.11. Nigeria Opioids Market by Application, Value (US$ Bn), 2018 - 2031
8.4.1.12. Nigeria Opioids Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.13. Rest of Middle East & Africa Opioids Market by Product, Value (US$ Bn), 2018 - 2031
8.4.1.14. Rest of Middle East & Africa Opioids Market by Application, Value (US$ Bn), 2018 - 2031
8.4.1.15. Rest of Middle East & Africa Opioids Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Product vs Application Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Pfizer, Inc.
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Boehringer Ingelheim International GmbH
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Janssen Pharmaceuticals, Inc.
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. Sanofi SAIS
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Sun Pharmaceutical Industries Ltd.
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Actavis Plc. [Teva Pharmaceutical Industries Ltd.]
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. Mallinckrodt Pharmaceuticals
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. Endo Pharmaceuticals Inc. [Endo International plc]
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Development
9.4.9. Purdue Pharma L.P.
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Development
9.4.10. Assertio Therapeutics, Inc. (Assertio Holdings, Inc.)
9.4.10.1. Company Overview
9.4.10.2. Product Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Development
10. Appendix
10.1.Research Methodology
10.2.Report Assumptions
10.3.Acronyms and Abbreviations

Companies Mentioned

  • Pfizer, Inc.
  • Boehringer Ingelheim International GmbH
  • Janssen Pharmaceuticals, Inc.
  • Sanofi SAIS
  • Sun Pharmaceutical Industries Ltd.
  • Actavis Plc. [Teva Pharmaceutical Industries Ltd.]
  • Mallinckrodt Pharmaceuticals
  • Endo Pharmaceuticals Inc. [Endo International plc]
  • Purdue Pharma L.P.
  • Assertio Therapeutics, Inc. (Assertio Holdings, Inc.)

Methodology

Loading
LOADING...